Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Susan, Malkiel"'
Autor:
Betty Diamond, Joyce Hui-Yuen, Kaiyu Jiang, Susan Malkiel, Barbara Anne Eberhard, Heather Walters, James Jarvis
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss 1 (2023)
Background SLE is likely triggered by gene–environment interactions. We have shown that most SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enhancer function in lymphocytes, suggesting genetic risk
Externí odkaz:
https://doaj.org/article/3be5afe2e0424205b0d85301fa2463fe
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 3 (2022)
Externí odkaz:
https://doaj.org/article/54e8abe27ada4e30a9d74e52439e91a2
Autor:
Ashley N. Barlev, Susan Malkiel, Izumi Kurata-Sato, Annemarie L. Dorjée, Jolien Suurmond, Betty Diamond
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 17 (2022)
FcγRIIB is an inhibitory receptor expressed throughout B cell development. Diminished expression or function is associated with lupus in mice and humans, in particular through an effect on autoantibody production and plasma cell (PC) differentiation
Externí odkaz:
https://doaj.org/article/dd187f23e3cf40549fffbeaae1ec3b5d
Autor:
Tam D. Quach, Weiqing Huang, Ranjit Sahu, Catherine M.M. Diadhiou, Chirag Raparia, Roshawn Johnson, Tung Ming Leung, Susan Malkiel, Peta Gay Ricketts, Stefania Gallucci, Çagla Tükel, Chaim O. Jacob, Martin L. Lesser, Yong-Rui Zou, Anne Davidson
Publikováno v:
JCI Insight, Vol 7, Iss 5 (2022)
TNF inhibitors are widely used to treat inflammatory diseases; however, 30%–50% of treated patients develop new autoantibodies, and 0.5%–1% develop secondary autoimmune diseases, including lupus. TNF is required for formation of germinal centers
Externí odkaz:
https://doaj.org/article/0bc079a9637640159ce2bb095af989d7
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/9111ba706e0b4d548abe0b434065fa88
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Plasma cells (PCs) are responsible for the production of protective antibodies against infectious agents but they also produce pathogenic antibodies in autoimmune diseases, such as systemic lupus erythematosus (SLE). Traditionally, high affinity IgG
Externí odkaz:
https://doaj.org/article/a19f6c1954e64ca0b6f5c72cae39c0f4
Autor:
Joyce S Hui-Yuen, Kaiyu Jiang, Susan Malkiel, B Anne Eberhard, Heather Walters, Betty Diamond, James N. Jarvis
BackgroundSystemic lupus erythematosus (SLE) is a complex disease likely triggered by gene-environment interactions. We have shown that most of the SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54404879411b08b7e318eedf6a6129b4
https://doi.org/10.1101/2022.09.23.509218
https://doi.org/10.1101/2022.09.23.509218
Autor:
Ashley N. Barlev, Susan Malkiel, Izumi Kurata-Sato, Annemarie L. Dorjée, Jolien Suurmond, Betty Diamond
Publikováno v:
Journal of Clinical Investigation, 132(17). AMER SOC CLINICAL INVESTIGATION INC
Fc gamma RIIB is an inhibitory receptor expressed throughout B cell development. Diminished expression or function is associated with lupus in mice and humans, in particular through an effect on autoantibody production and plasma cell (PC) differenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3fdb6f41c79f766302010381da0fecf
https://hdl.handle.net/1887/3562181
https://hdl.handle.net/1887/3562181
Autor:
Joyce Hui-Yuen, Kaiyu Jiang, Susan Malkiel, Barbara Anne Eberhard, Heather Walters, Betty Diamond, James Jarvis
Publikováno v:
Lupus Science & Medicine. 10:e000921
BackgroundSLE is likely triggered by gene–environment interactions. We have shown that most SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enhancer function in lymphocytes, suggesting genetic risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed7e802ad9bd6210f2ae71116e9e249a
https://doi.org/10.1136/lupus-2023-000921
https://doi.org/10.1136/lupus-2023-000921
Autor:
Wendy Gao, Margie Byron, Betty Diamond, Diane L. Kamen, Maria Dall'Era, Cynthia Aranow, Anca D. Askanase, Amit Saxena, Susan A. Boackle, Kristin Ryker, Linna Ding, Patti Tosta, Sai Kanaparthi, Kristina M. Harris, Samir V. Parikh, Kyriakos A. Kirou, Maureen McMahon, S. Sam Lim, William F. Pendergraft, David Wofsy, Dawn E. Smilek, W. Winn Chatham, Susan Malkiel, Amber S. Podoll, Bradley Marder, Y Atisha-Fregoso, William T. Barry, David R. Karp
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis Rheumatol
Arthritis Rheumatol
Objective To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN). Methods In a multicenter, randomized, open-label clinical trial, 43 patients with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70c4b88b5e4839396236501e0fd9ad4a
http://europepmc.org/articles/PMC7839443
http://europepmc.org/articles/PMC7839443